The estimated Net Worth of Burton G Malkiel is at least $842 Thousand dollars as of 21 May 2018. Burton Malkiel owns over 1,000 units of Theravance Biopharma Inc stock worth over $459,732 and over the last 10 years he sold TBPH stock worth over $0. In addition, he makes $381,879 as Independent Director at Theravance Biopharma Inc.
Burton has made over 3 trades of the Theravance Biopharma Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 1,000 units of TBPH stock worth $22,540 on 21 May 2018.
The largest trade he's ever made was buying 30,000 units of Theravance Biopharma Inc stock on 11 August 2017 worth over $737,700. On average, Burton trades about 3,154 units every 77 days since 2014. As of 21 May 2018 he still owns at least 56,757 units of Theravance Biopharma Inc stock.
You can see the complete history of Burton Malkiel stock trades at the bottom of the page.
Dr. Burton G. Malkiel Ph.D. serves as Independent Director of the Company., serves as an Independent Director of the Company. Prior to our spin-off from Innoviva, Inc. ("Innoviva") in June 2014 and since July 2007, Dr. Malkiel served as a director of Innoviva. Dr. Malkiel is the Chief Investment Officer and chair of the Investment Committee at Wealthfront, Inc., a private investment company, a position he has held since November 2012, and the Chemical Bank Chairman's Professor of Economics, Emeritus, and Senior Economist at Princeton University, a position he has held since July 2011 following positions as a senior research economist and professor at Princeton University since 1988. Dr. Malkiel is the author of A Random Walk Down Wall Street and over 125 articles and is the author or co-author of nine other books. From 1981 to 1988 he was dean of the Yale University School of Management and also served as the William S. Beinecke Professor of Management Studies. He is a past appointee to the President's Council of Economic Advisors. In addition, Dr. Malkiel currently serves on the board of directors of several corporations including Genmab AS and served on the board of directors of The Vanguard Group Ltd. until March 2015. He also serves on several investment management boards including the Investment Committees for the American Philosophical Association and Alpha Shares, LLC. He is a past president of the American Finance Association and the International Atlantic Economic Association. He holds a B.A. and M.B.A. degree from Harvard University and a Ph.D. degree from Princeton University. Dr. Malkiel's demonstrated leadership in his field, his knowledge of financial and financing matters, and his ability to serve as a financial expert on our audit committee contributed to our board's conclusion that he should serve as a director.
As the Independent Director of Theravance Biopharma Inc, the total compensation of Burton Malkiel at Theravance Biopharma Inc is $381,879. There are 12 executives at Theravance Biopharma Inc getting paid more, with Rick Winningham having the highest compensation of $5,932,410.
Burton Malkiel is 87, he's been the Independent Director of Theravance Biopharma Inc since 2013. There are no older and 27 younger executives at Theravance Biopharma Inc.
Burton's mailing address filed with the SEC is C/O THERAVANCE BIOPHARMA US, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 10 years, insiders at Theravance Biopharma Inc have traded over $11,619,559 worth of Theravance Biopharma Inc stock and bought 4,008,513 units worth $29,986,832,769,275 . The most active insiders traders include Plc Gsk, Inc. Innoviva,, and Eli Samaha. On average, Theravance Biopharma Inc executives and independent directors trade stock every 57 days with the average trade being worth of $448,635. The most recent stock trade was executed by Eli Samaha on 7 August 2024, trading 999,800 units of TBPH stock currently worth $7,798,440.
theravance biopharma is a biopharmaceutical company with one approved product, vibativ® (telavancin), that was discovered and developed internally, a pipeline of internally discovered product candidates and strategic collaborations with pharmaceutical companies.
Theravance Biopharma Inc executives and other stock owners filed with the SEC include: